Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15451277 | 0.85 | CTRB1 (0.39) | CTSSCTSLACE | |
| SCHEMBL15451276 | 0.85 | CTRB1 (0.39) | CTSSCTSLACE | |
| SCHEMBL223571 | 0.84 | PPARA (0.52) | PPARACTSSSYKATMPPARG | |
| SCHEMBL29401143 | 0.84 | PPARA (0.51) | PPARACTSSSYKATMKLK5 | |
| SCHEMBL2350194 | 0.84 | PPARA (0.51) | PPARACTSSSYKATMKLK5 | |
| SCHEMBL28594865 | 0.79 | PPARA (0.60) | PPARACTSSSYKATMKLK5 | |
| SCHEMBL28594867 | 0.79 | PPARA (0.60) | PPARACTSSSYKATMKLK5 | |
| SCHEMBL4468177 | 0.78 | PPARA (0.52) | PPARACTSSSYKATMPPARG | |
| SCHEMBL2447896 | 0.77 | PSMB5 (0.40) | PPARACTSSSYKRAB9ACTSL | |
| SCHEMBL3196374 | 0.77 | PPARA (0.61) | PPARACTSSSYKATMKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642632-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120004270-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004270-A1 | Selective Androgen Receptor Modulators | AR, NR3C2, NR5A1 | PPARA 133/4885CTSS 4795/4885SYK 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.